IDH1 and neoplasm: To this end, we have subjected patient-derived tumor cells from an R132C IDH1 mutant astrocytoma (grade III) patient (PD-AS) and an IDH1 wild-type (grade IV) glioblastoma patient (PD-GB) to label-free quantitative proteome profiling.